Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Fabrinet (FN) vs Zoetis Inc (ZTS) Price & Performance

Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Fabrinet vs Zoetis Inc — how do they compare? Fabrinet trades at $575 (market cap $18.84B), while Zoetis Inc trades at $73.63 (market cap $31.14B). The key difference: Zoetis Inc is the larger of the two by market cap, and Zoetis Inc pays a 2.81% dividend while Fabrinet pays none. Which is the better fit depends on your goals.

FNZTS
Market Cap
$18.84B$31.14B
Sector
TechnologyHealth
52-Week High
$746.47$156.76
52-Week Low
$277.04$71.91
Enterprise Value
$17.90B$38.70B
Dividend Yield
2.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Fabrinet

Fabrinet (FN) trades at $583.95, up 10.79% in 24 hours, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $3.81. Revenue grew to $3.42 billion in 2025, with a net income margin of 9.94%, while the company maintains a debt-free balance sheet and strategic positioning in AI optical supply chains.

Outlook is positive due to robust AI-driven demand and expansion plans, though risks include premium valuation (P/E 45.18) and supply chain constraints. Analysts are bullish with 75% buy ratings and a $661.75 price target (MarketBeat, 2026-07-07), but technical indicators suggest near-term resistance near $532.

Zoetis Inc

Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.

The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Fabrinet

Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.

Read more on FN

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS